Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

• Status: Not yet recruiting
• Trial end date: 2026-10-01

Summary

The objective of this study was to evaluate the therapeutic effect of nafamostat mesilate on patients with severe infection-related coagulation。

• Phase: Phase 4

Details

• Lead Sponsor: Xu Li
• Collaborators: Anhui Provincial Hospita; Benxi Cental Hospital; Dalian NO.3 People's Hospital; First Affiliated Hospital of Xinjiang Medical University; Genertec Liaoyou Gem Flower Hospital; Hohhot First Hospital; Huludao central hospital; LanZhou University; Liaoyang City Central Hospital; Northern Jiangsu People's Hospital; Shanxi Bethune Hospital; Shanxi Provincial People's Hospital; The Affiliated Hospital of Nantong University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital of Gannan Medical University; The First Affiliated Hospital of Liaoning; The First Affiliated Hospital of Ningbo; The First Affiliated Hospital of Suzhou Medical; The First Affiliated Hospital of Wenzhou; The First Affiliated Hospital of Xinjiang; The First Bethune Hospital Jilin University; The Fourth Affiliated Hospital of China Medical; The Jiangxi Provincial People's Hospital; The Second Affiliated Hospital Xi'an Jiaotong; The Second Hospital University of South China; The Sixth People's Hospital of Shenyang; The Tenth People's Hospital of Shenyang; Tianjin Medical University General Hospital; Tianjin Third Central Hospital; Tongji Medical College of Huazhong University; Zhejiang Hospital; Zhejiang Provincial People's Hospital
• Treatments: Nafamostat